Business
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, March 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the granting of two globa
About this update from Gri Bio, Inc.
[{"type":"image","alt":"GRI Bio, Inc.","displaySize":"","headline":null,"caption":"GRI Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":298,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VpQzftFLIZDIqhYm6TSWfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54d4b237b8db6f5a566b8418ca0ae02c","width":298,"height":144}},"lazy":false},{"type":"text","content":"Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases","length":181,"tagName":"p"},{"type":"text","content":"LA JOLLA, CA, March 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the granting of two global patents.","length":328,"tagName":"p"},{"type":"text","content":"The granted patents include:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Europe patent application No. 19,166,502 titled, “Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.” The patent claims include coverage of GRI-0803, the Company’s novel activator of human type 2 diverse NKT (dNKT) cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus (SLE). Activation of dNKT leads to a dendritic cell-mediated inhibition of type 1 invariant NKT (iNKT) cells.","length":518,"tagName":"p"}]},{"val":[{"type":"text","content":"Japan application No. 2023-000750 titled, “Prevention and Treatment of Inflammatory Conditions.” This patent covers claims including compositions and methods for modulating dNKT and/or iNKT cells in the prevention and treatment of inflammatory conditions. More specifically, the patent covers the prevention and treatment of inflammatory, fibrotic and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist that inhibits iNKT cells in a subject.","length":481,"tagName":"p"}]}],"tagName":"ul","bu...